JP2017158561A5 - - Google Patents

Download PDF

Info

Publication number
JP2017158561A5
JP2017158561A5 JP2017077422A JP2017077422A JP2017158561A5 JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5 JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017077422 A JP2017077422 A JP 2017077422A JP 2017158561 A5 JP2017158561 A5 JP 2017158561A5
Authority
JP
Japan
Prior art keywords
inflammatory
seq
composition according
composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017077422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017158561A (ja
JP6514259B2 (ja
Filing date
Publication date
Priority claimed from KR1020120079096A external-priority patent/KR20140012385A/ko
Priority claimed from KR1020120089167A external-priority patent/KR20140022699A/ko
Priority claimed from KR1020120089162A external-priority patent/KR20140022698A/ko
Application filed filed Critical
Publication of JP2017158561A publication Critical patent/JP2017158561A/ja
Publication of JP2017158561A5 publication Critical patent/JP2017158561A5/ja
Application granted granted Critical
Publication of JP6514259B2 publication Critical patent/JP6514259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017077422A 2012-07-20 2017-04-10 抗炎症活性を有するペプチド、及びそれを含む組成物 Active JP6514259B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
KR10-2012-0079096 2012-07-20
KR1020120079096A KR20140012385A (ko) 2012-07-20 2012-07-20 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물
KR1020120089167A KR20140022699A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR20120089161 2012-08-14
KR10-2012-0089167 2012-08-14
KR10-2012-0089161 2012-08-14
KR10-2012-0089162 2012-08-14
KR1020120089162A KR20140022698A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR10-2012-0104144 2012-09-19
KR10-2012-0104207 2012-09-19
KR20120104207 2012-09-19
KR20120104144 2012-09-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015521997A Division JP6352911B2 (ja) 2012-07-20 2013-03-15 抗炎症活性を有するペプチド、及びそれを含む組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019075635A Division JP6788062B2 (ja) 2012-07-20 2019-04-11 抗炎症活性を有するペプチド、及びそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2017158561A JP2017158561A (ja) 2017-09-14
JP2017158561A5 true JP2017158561A5 (cg-RX-API-DMAC7.html) 2018-11-22
JP6514259B2 JP6514259B2 (ja) 2019-05-15

Family

ID=47882177

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015521997A Active JP6352911B2 (ja) 2012-07-20 2013-03-15 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2017077422A Active JP6514259B2 (ja) 2012-07-20 2017-04-10 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2019075635A Active JP6788062B2 (ja) 2012-07-20 2019-04-11 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2020181780A Active JP7128246B2 (ja) 2012-07-20 2020-10-29 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2022130519A Active JP7440581B2 (ja) 2012-07-20 2022-08-18 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024021407A Active JP7741218B2 (ja) 2012-07-20 2024-02-15 抗炎症活性を有するペプチド、及びそれを含む組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015521997A Active JP6352911B2 (ja) 2012-07-20 2013-03-15 抗炎症活性を有するペプチド、及びそれを含む組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019075635A Active JP6788062B2 (ja) 2012-07-20 2019-04-11 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2020181780A Active JP7128246B2 (ja) 2012-07-20 2020-10-29 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2022130519A Active JP7440581B2 (ja) 2012-07-20 2022-08-18 抗炎症活性を有するペプチド、及びそれを含む組成物
JP2024021407A Active JP7741218B2 (ja) 2012-07-20 2024-02-15 抗炎症活性を有するペプチド、及びそれを含む組成物

Country Status (8)

Country Link
US (6) US20150125438A1 (cg-RX-API-DMAC7.html)
EP (3) EP3428182B1 (cg-RX-API-DMAC7.html)
JP (6) JP6352911B2 (cg-RX-API-DMAC7.html)
KR (2) KR20150031413A (cg-RX-API-DMAC7.html)
CN (3) CN104470947B (cg-RX-API-DMAC7.html)
ES (2) ES2871899T3 (cg-RX-API-DMAC7.html)
TW (6) TWI836435B (cg-RX-API-DMAC7.html)
WO (1) WO2014012683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320058D0 (en) 1993-09-29 1993-11-17 Gillette Co Savety razors
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2873678B8 (en) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
ES2999332T3 (en) 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US9797889B2 (en) * 2013-03-15 2017-10-24 Promega Corporation Activation of bioluminescence by structural complementation
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
KR102224965B1 (ko) * 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー,リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
US10744179B2 (en) * 2014-09-18 2020-08-18 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
KR101662438B1 (ko) * 2015-04-07 2016-10-04 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
WO2017003267A1 (ko) * 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CA2996951C (en) * 2015-08-28 2024-05-07 The Medical College Of Wisconsin, Inc. Peptide inhibitors of telomerase translocation and therapeutic uses thereof
AU2016321333A1 (en) * 2015-09-09 2018-04-26 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR101831888B1 (ko) 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN110248953A (zh) * 2016-12-22 2019-09-17 蒙彼利埃大学 新型订书肽及其用途
JP6601848B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
JP6601849B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
KR102092843B1 (ko) * 2018-08-30 2020-03-24 충남대학교 산학협력단 암 예방 또는 치료용 펩타이드 및 이의 용도
KR102274658B1 (ko) * 2018-11-16 2021-07-09 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
KR102032945B1 (ko) * 2018-12-03 2019-10-16 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR102146937B1 (ko) * 2018-12-11 2020-08-21 대한민국 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
CN117015392A (zh) * 2021-02-08 2023-11-07 巴克巴有限公司 皮肤病症的治疗
KR20230156265A (ko) * 2022-05-03 2023-11-14 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도
KR102827929B1 (ko) * 2023-01-26 2025-07-09 ㈜에빅스젠 신규한 뇌 질환 치료제 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
CN1231491C (zh) * 1994-07-07 2005-12-14 杰龙公司 哺乳动物端粒酶
CN1080260C (zh) * 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
AU748442B2 (en) * 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
JP2005523236A (ja) * 2001-07-31 2005-08-04 ペプジェン コーポレイション 免疫応答調節組成物および方法
CA2456369A1 (en) * 2001-08-08 2003-02-20 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
US8492438B2 (en) * 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
WO2004099377A2 (en) * 2003-05-01 2004-11-18 Musc Foundation For Research Development An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN101011571A (zh) * 2006-03-13 2007-08-08 上海交通大学医学院 GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用
US9487574B2 (en) * 2006-09-21 2016-11-08 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN101522706B (zh) * 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
RU2472784C2 (ru) 2007-05-18 2013-01-20 Инхайбокс Лтд. Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтических агентов
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
JP5787752B2 (ja) * 2008-06-16 2015-09-30 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 抗腫瘍免疫療法
US8252282B2 (en) * 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
US20110183925A1 (en) 2008-09-22 2011-07-28 Nisshin Pharma Inc. Anti-inflammatory peptide
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP3581649A1 (en) * 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptides
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
ES2999332T3 (en) 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
CN105535931A (zh) * 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
KR102224965B1 (ko) 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Similar Documents

Publication Publication Date Title
JP2017158561A5 (cg-RX-API-DMAC7.html)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
RU2017101705A (ru) Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii
JP2015517488A5 (cg-RX-API-DMAC7.html)
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
CN111344398A (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP2018509388A5 (cg-RX-API-DMAC7.html)
JP2014515763A5 (cg-RX-API-DMAC7.html)
JP2016506416A5 (cg-RX-API-DMAC7.html)
JP2017503820A5 (cg-RX-API-DMAC7.html)
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
RU2020126034A (ru) Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
JPWO2019107530A5 (cg-RX-API-DMAC7.html)
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
LeMessurier et al. Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice
JP2019533722A5 (cg-RX-API-DMAC7.html)
Liu et al. Chrysin ameliorates influenza virus infection in the upper airways by repressing virus-induced cell cycle arrest and mitochondria-dependent apoptosis
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
EP4225382A4 (en) ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
JP2019531293A5 (cg-RX-API-DMAC7.html)
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
Ke et al. Curcumin-activated autophagy plays a negative role in its anti-osteoclastogenic effect
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
Ellerhoff et al. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
JP2018524306A5 (cg-RX-API-DMAC7.html)